In a report released on April 17, Conor McNamara from RBC Capital maintained a Buy rating on Avantor (AVTR – Research Report), with a price target of $29.00. The company’s shares closed yesterday at $24.30.
According to TipRanks, McNamara is an analyst with an average return of -12.5% and a 29.47% success rate. McNamara covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Bio-Rad Laboratories, and Danaher.
In addition to RBC Capital, Avantor also received a Buy from Bank of America Securities’s Michael Ryskin in a report issued on April 17. However, yesterday, Deutsche Bank maintained a Hold rating on Avantor (NYSE: AVTR).
The company has a one-year high of $26.16 and a one-year low of $16.63. Currently, Avantor has an average volume of 5.52M.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AVTR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avantor (AVTR) Company Description:
Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates in more than 30 countries and deliver an extensive portfolio of products and services. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.
